Pharmafile Logo

transcreation

- PMLiVE

Moderna and CEPI enter pandemic preparedness partnership

The partnership aims to expand infectious disease targets for mRNA vaccine technology

- PMLiVE

Candel announces promising results for immunotherapy candidate in pancreatic cancer

Pancreatic cancer accounts for approximately 3.3% of all new cancer cases

- PMLiVE

New UK research institute launched for motor neurone disease

The research institute will bring together MND labs, clinical centres and researchers

- PMLiVE

International study reveals how to measure long COVID severity and impact

A set of 12 recommendations were established for scientific and clinical communities

- PMLiVE

Multi-award-winning healthcare communications agency fox&cat scoops PR Week’s New Consultancy of the Year 2023

Recognised for its focus on wellbeing and its unique, lean and agile agency model, integrated healthcare communications agency, fox&cat has won ‘New Consultancy of the Year’ at PR Week’s 2023...

Fox&Cat

- PMLiVE

Eli Lilly exercises option to progress autoimmune and inflammatory disease therapy

The move triggers an undisclosed milestone payment to Lilly’s partner Sitryx Therapeutics

- PMLiVE

Abu Dhabi launches clinical genomic medicine and genetic counselling programme

More than 400,000 genetic samples have been collected as part of the programme

- PMLiVE

Alzheimer’s Research UK survey highlights dementia knowledge gaps

The UK poll revealed that only 60% of adults know that dementia is a cause of death

- PMLiVE

Merck shares positive results for adjuvant Keytruda in phase 3 kidney cancer trial

Renal cell carcinoma accounts for approximately 90% of all kidney cancer diagnoses

- PMLiVE

Study reveals cancer drug could be used to treat inflammatory diseases

Researchers plan to test the drug against inflammatory diseases in clinical trials

- PMLiVE

Discovery Park marks decade of growth with first Innovation Summit

The event focused on how technology and AI are advancing and revolutionising the sector

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links